Cynosure Group LLC Increases Holdings in Humana Inc. (NYSE:HUM)

Cynosure Group LLC increased its position in Humana Inc. (NYSE:HUM) by 11.2% during the 3rd quarter, Holdings Channel reports. The firm owned 1,324 shares of the insurance provider’s stock after acquiring an additional 133 shares during the quarter. Cynosure Group LLC’s holdings in Humana were worth $419,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of HUM. FMR LLC lifted its holdings in shares of Humana by 23.4% in the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock worth $1,073,387,000 after buying an additional 643,291 shares during the period. Pzena Investment Management LLC lifted its stake in Humana by 8.1% in the third quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock worth $793,830,000 after acquiring an additional 187,903 shares during the period. Davis Selected Advisers grew its holdings in Humana by 16.1% during the 2nd quarter. Davis Selected Advisers now owns 2,311,362 shares of the insurance provider’s stock worth $863,640,000 after acquiring an additional 321,233 shares in the last quarter. Marshall Wace LLP increased its position in Humana by 118.9% during the 2nd quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock valued at $532,564,000 after purchasing an additional 774,085 shares during the period. Finally, Legal & General Group Plc raised its holdings in shares of Humana by 2.1% in the 2nd quarter. Legal & General Group Plc now owns 1,183,985 shares of the insurance provider’s stock valued at $442,396,000 after purchasing an additional 24,842 shares in the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Stock Up 0.4 %

Shares of HUM stock opened at $296.83 on Thursday. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $526.47. The firm has a market capitalization of $35.74 billion, a PE ratio of 26.29, a P/E/G ratio of 2.40 and a beta of 0.52. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. The stock’s 50-day simple moving average is $275.91 and its 200-day simple moving average is $330.00.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. The company had revenue of $29.30 billion during the quarter, compared to analyst estimates of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. Equities analysts expect that Humana Inc. will post 15.86 earnings per share for the current year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.19%. The ex-dividend date is Tuesday, December 31st. Humana’s payout ratio is presently 31.36%.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on HUM. TD Cowen increased their price objective on shares of Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Barclays increased their target price on Humana from $250.00 to $253.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Royal Bank of Canada reduced their price target on Humana from $400.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. KeyCorp started coverage on Humana in a research report on Friday, October 11th. They set a “sector weight” rating on the stock. Finally, Leerink Partners downgraded shares of Humana from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $400.00 to $250.00 in a report on Wednesday, October 2nd. Twenty equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $315.86.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.